Himension Capital Singapore PTE. LTD. Trims Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Himension Capital Singapore PTE. LTD. lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 0.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,770 shares of the company’s stock after selling 375 shares during the period. Himension Capital Singapore PTE. LTD. owned about 0.09% of CRISPR Therapeutics worth $3,179,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of CRSP. Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics during the 4th quarter worth approximately $39,000. Western Pacific Wealth Management LP boosted its stake in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics in the third quarter worth about $40,000. Spire Wealth Management increased its stake in CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock worth $78,000 after buying an additional 1,482 shares during the period. Finally, MCF Advisors LLC bought a new stake in CRISPR Therapeutics during the 4th quarter valued at about $80,000. Institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Greene purchased 7,000 shares of the company’s stock in a transaction on Wednesday, February 26th. The shares were purchased at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the purchase, the director now owns 7,000 shares in the company, valued at approximately $313,950. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 32,381 shares of company stock worth $1,608,243. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $32.65 on Friday. The firm has a market capitalization of $2.80 billion, a P/E ratio of -7.47 and a beta of 1.85. The business’s 50-day moving average is $42.15 and its 200 day moving average is $44.67. CRISPR Therapeutics AG has a 1 year low of $30.96 and a 1 year high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Wall Street Analysts Forecast Growth

CRSP has been the topic of a number of research analyst reports. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a research note on Wednesday, February 12th. Morgan Stanley increased their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research note on Friday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Finally, Bank of America cut their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and an average price target of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.